Evidence that a STAT3 Mutation Causing Hyper IgE Syndrome Leads to Repression of Transcriptional Activity by Bahal, S et al.
Case Report
Evidence that a STAT3 Mutation Causing Hyper IgE Syndrome 
Leads to Repression of Transcriptional Activity
Sameer Bahal ,1 Maha E. Houssen,2,3 Ania Manson,4 Lorena Lorenzo,1 Mark A. Russell,2 
Noel G. Morgan,2 Fariba Tahami,5 and Sofia Grigoriadou 1
1Department of Immunology, Royal London Hospital, Barts Health NHS Trust, London, UK
2University of Exeter Medical School, UK
3Biochemistry Department, Damanhour University, Egypt
4Department of Immunology, Addenbrooke’s Hospital, Cambridge, UK
5Department of Immunology, Great Ormond Street Hospital, London, UK
Correspondence should be addressed to Sameer Bahal; s.bahal@nhs.net
Received 15 May 2019; Revised 17 July 2019; Accepted 28 July 2019; Published 13 October 2019
Academic Editor: Elena Bozzola
Copyright © 2019 Sameer Bahal et al. is is an open access article distributed under the Creative Commons Attribution License, 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
We present the case of a 19-year-old female with a mild form of Autosomal Dominant Hyper IgE syndrome (HIES) associated 
with a loss-of-function mutation in STAT3. Within the rst years of life she developed multiple, Staphylococcus aureus associated 
abscesses in the neck and face requiring frequent incision and drainage. Respiratory tract infections were not a feature of the 
clinical phenotype and a high resolution thoracic CT scan was unremarkable. Retained dentition was noted but fungal nail disease 
and recurrent thrush were absent. e total IgE was 970 IU/L, Lymphocyte counts and immunoglobulin levels were normal (IgG 
borderline 18.5 gr/L). ere was suboptimal response to test immunisation with Pneumovax II vaccine. 17 cell phenotyping 
revealed low levels of IL-17 expressing cells (0.3% of total CD4 T Cells numbers). Genetic analysis identied a missense mutation, 
N567D, in a conserved region of the linker domain of STAT3. Functional studies in HEK293 cells reveal that this mutation potently 
inhibits STAT3 activity when compared to the wildtype protein. is is consistent with other reported mutations in STAT3 associated 
with HIES. However, surprisingly, the magnitude of inhibition was similar to another STAT3 mutation (V637M) which causes a 
much more severe form of the disease.
1. Introduction
Hyper IgE syndrome (HIES) is a rare primary immune de-
ciency and is characterised by elevated circulating levels of 
IgE. Patients typically experience eczema, lung, and skin infec-
tions, but other co-morbidities have also been described 
including brain and cardiac abnormalities. e autosomal 
dominant form of HIES is most commonly associated with 
inactivating mutations in STAT3 although HIES-associated 
mutations in DOCK8 and Tyk2 are reported [1].
e transcription factor STAT3 is a multifunctional pro-
tein, whose activity is controlled by a plethora of cytokines 
and growth factors acting at their cognate cell surface recep-
tors. Activated STAT3 translocates to the nucleus where it 
binds to consensus sequences in the DNA to regulate target 
gene expression. A variety of mutations in STAT3 have been 
implicated in disease and, in addition to loss-of-function 
mutations associated with HIES [2], various activating muta-
tions have also been described which may predispose to cer-
tain forms of cancer [3], autoimmune forms of neonatal 
diabetes, and various immune deciencies [4], including 
CVID [5]. In the current report, we performed sequencing of 
samples from a patient with a mild form of HIES, to identify 
a missense mutation in the linker domain of STAT3 which 
caused a reduction in transcriptional activity and is likely to 
be causative for disease.
2. Patient Description
We present the case of a 19-year-old female with Autosomal 
Dominant HIES. She was born at 36 weeks gestation and early 
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in life she developed multiple, Staphylococcus aureus associ-
ated abscesses in the neck and face requiring frequent incision 
and drainage. Respiratory tract infections were not a feature 
of the clinical phenotype and a thoracic CT scan was unre-
markable. Retained dentition and mild eczema were noted but 
fungal nail disease and recurrent thrush were absent. e cir-
culating total IgE was markedly elevated (970 IU/L, NR: 
0-81 IU/L); T and B cell counts were normal but IgG was raised 
(18.5 gr/L). Complement C3 and C4 levels, and complement 
function tests were normal. ere was a suboptimal response 
to test immunisation with Pneumovax II vaccine. e patient 
is currently managed with flucloxacillin 500 mg BD for 
Staphylococcus aureus prophylaxis. e disease activity  cal-
culated via the score previously described by Grimbacher 
et al. was 36 [6]. is is classed as indicating an indeterminate 
risk of HIES and reflects the mild/moderate phenotype [7].
3. Materials and Methods
3.1. Sanger Sequencing. Genomic DNA was isolated from 
whole blood. Coding genomic sequences and cDNA of 
STAT3 were purified with the QIAquick PCR purification kit 
(Qiagen, Hilden, Germany). Subsequently, PCR products were 
sequenced using the ABI PRISM BigDye Terminator cycle 
ready reaction kit V3.1 (Applied Biosystems). e sequencing 
was performed on a 3130xl Applied Biosystems Genetic 
Analyzer. Data analysis was performed with DNA Sequencing 
Analysis soware, v5.2 (Applied Biosystems) and Sequencher 
v4.8 (Gene Codes Corp, Ann Arbor, Mich).
3.2. Cell Culture. A DMEM base medium supplemented 
with 10% foetal calf serum, 2 mM L-glutamine, 100 μg/ml 
streptomycin, and 100 U/ml penicillin was used to culture 
HEK293 cells. Cells were sub-cultured upon reaching 
approximately 80% confluency.
3.3. Mutagenesis. Mutations within the human STAT3 gene 
(Source Bioscience, Nottingham, UK) were introduced 
using the QuikChange site-directed mutagenesis kit (Agilent 
Technologies, CA, USA). e custom primers used to 
generate STAT3 variants were N567D; Fd ACAAGGT-
CAATGATATCGTCCAGCCAGACCCAG Rv: TCTGG-
GTCTGGCTGGACGATATCATTGACCTTGTG Y640F; 




GGGTC. e success of mutagenesis was confirmed by full 
sequencing of inserts (Source Bioscience). e STAT3 inserts 
were digested out of a pENTR221 vector using PsiI to produce 
a blunt-ended product. is was treated with a calf intestinal 
phosphatase enzyme prior to insertion into a pcDNA5/FRT/
TO expression vector at the EcoRV restriction site within the 
polylinker.
3.4. Reporter Assay. HEK293 cells were seeded into 24-well 
plates and transfected with 200 ng of the STAT3-reponsive 
dual luciferase Cignal reporter construct (Qiagen) and 400 ng 
of the various STAT3 constructs. Attractene transfection 
reagent (Qiagen) was used to facilitate DNA uptake, and 
STAT3 activity was assessed 24 h aer transfection using a dual 
luciferase reporter assay system (Promega, Madison, WI, USA) 
and with luminescence detected using a Pherastar FS (BMG 
Labtech, Ortenberg, Germany). In some experiments, cells 
were treated with human IL-6 (R&D systems, Minneapolis, 
MN, USA) 4 h aer transfection.
3.5. Western Blotting. Cells were lysed and whole cell protein 
was extracted [8]. Protein was denatured, loaded evenly onto 
a 4%–12.5% Bis-Tris polyacrylamide gel and separated by 
electrophoresis. Protein was then transferred onto a PVDF 
membrane prior to immunoblotting using an iBind Flex 
according to the manufacturer’s guidelines (ermo Fisher 
Scientific). Membranes were probed with STAT3 antisera 
(1 : 1000; Cell Signalling, Beverly, MA, USA) or beta-actin 
(1 : 2000; Sigma-Aldrich, Poole, Dorset, UK), and then with 
appropriate alkaline phosphatase conjugated secondary 
antibodies. CDP Star chemiluminescent reagent (Sigma-
Aldrich) was used to detect bands, and this was visualised 
using a cDigit blot scanner.
3.6. 17 Phenotyping. PBMCs were isolated from a 10 ml 
heparin blood sample using LymphoprepTM (Axis-Shield). 
e PBMCs were re-suspended in 4 ml of RPMI with 10% 
foetal bovine serum. Cells were either untreated or stimulated 
with 1 µg/mL Staphylococcus enterotoxin B (SEB; Sigma) for 
2 h. GolgiStop (BD Biosciences) was then added and cells 
were incubated for a further 16 h. Subsequently, cells were 
surface stained with CD3 (V500), CD4 (V450), and CD45RO 
(PerCP-Cy5.5) and intracellular stained with IL-4 (PE-Cy7), 
IFN-γ (Alexa Fluor®488), and IL-17A (Alexa Fluor®647). 
Intracellular staining was performed by using the BD Cytofix/
Cytoperm™ Fixation/Permeabilization Kit (BD Biosciences). 
All antibodies were from BD Biosciences. Cells were analysed 
using an 8 colour BD FACSCanto.
4. Results
4.1. 17 Profiling of Patient. HIES patients typically display 
reduced numbers of 17 T-helper cells [9]. 17 cell 
phenotyping revealed that 17 cells comprised 0.3% of the 
total CD4+ T-cell number. is was below the normal range 
of >0.4%, and consistent with the diagnosis of Hyper IgE 
syndrome.
4.2. Functional Investigations. Sanger sequencing of the 
patient’s DNA revealed a missense mutation in the STAT3 
gene. e variant was heterozygous with a nucleotide exchange 
(A to G) at position 1699 in exon 19, leading to an aspartate 
for asparagine substitution at position 567 within the linker 
domain (N567D) (Figure 1). e amino acid sequence is 
highly conserved at this region across multiple species [10].
e N567D variant of STAT3 was generated by site-di-
rected mutagenesis, and upon transfection into HEK293 cells, 
Western blotting analysis revealed an increase in STAT3 
expression compared to cells transfected with empty vector 
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(Figure 2(a)). Importantly, transfection of either the wildtype 
(WT) or mutant form of STAT3 resulted in approximately 
equal levels of protein expression (Figure 2(a)).
To study the impact of N567D on STAT3 transcriptional 
activity, a STAT3-responsive dual-luciferase reporter construct 
was employed, and this revealed that STAT3-N567D signi-
cantly inhibited protein activity compared to WT STAT3 (fold 
change from WT; N567D: 0.6 ± 0.2,  < 0.05) (Figure 2(b)). 
IL-6 is an agonist of STAT3 signalling, and treatment of 
HEK293 cells with 20 ng/ml IL-6 enhanced STAT3 activity by 
~14-fold in cells expressing WT STAT3. Under IL-6 stimulated 
conditions the inhibitory e©ects of N567D were more pro-
nounced, and STAT3 activity was reduced to levels comparable 
to those seen in unstimulated cells expressing WT STAT3 
(Figure 2(b)). It is important to emphasise that, in these stud-
ies, expression of the mutant form was achieved in the context 
of the continued expression of the endogenous (wild type) 
STAT3 present in HEK293 cells. As such, the data are likely to 
be reªective of the situation occurring in vivo when a domi-
nant heterozygous mutations is found.
To validate the assay system, previously reported STAT3 
mutations which enhance (Y640F) or reduce (V637M) STAT3 
activity were tested in parallel with N567D. STAT3 activity 
was modied in the expected direction under both basal and 
IL-6 stimulated conditions upon the transfection of cells with 
these variants (Figures 2(a) and  2(b)).
5. Discussion
Autosomal dominant HIES is caused by loss-of-function 
mutations in STAT3 [11]. Consistent with this, we describe a 
de novo mutation in the linker domain of STAT3 from a patient 
with a mild/moderate form of HIES that robustly inhibited 
the activity of STAT3 under both basal and IL-6 stimulated 
conditions. is mutation has been described in a single 
N-term Coiled coil DNA binding Linker SH2 Trans-activation
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Figure 2: Transfection of N567D-STAT3 into cells increased STAT3 activity. (a) HEK293 cells were transfected with equal amounts of an empty 
vector, wildtype STAT3 or N567D and expression of STAT3 was studied by Western blotting. Results are representative of two independent 
experiments. (b) Cells were alternatively transfected with wildtype, N567D, and mutations which are known to activate (Y640F), and inactivate 
(V637M) STAT3. ese cells were either grown in the presence or absence of 20 ng/ml IL-6 for 18 h, and transcriptional activity was determined 
using a dual-luciferase reporter assay ( = 3 − 6). ∗ < 0.05.
(a)
(b)
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